Bibliografía

Viktor E. Frankl: Un psicólogo en el campo de concentración, Buenos Aires, 1955. Editorial Plantin / Viktor E. Frankl: La psicoterapia en la Práctica médica, Buenos Aires, 1956. Editorial Plantin, 287 pp.  / Viktor E. Frankl: El hombre incondicionado, Buenos Aires, Editorial Plantin, 184 pp. / Viktor E. Frankl: Homo patiens (Intento de una patodicea), Buenos Aires, 1955. Editorial Plantin, 167 pp. / Viktor E. Frankl: El Dios inconsciente. Buenos Aires, 1955. Editorial Plantin. / J. Nuttin: Psicoanálisis y concepción espiritualista del hombre. Traducción de la segunda edición francesa por el doctor E. García Moreno. Biblioteca Nueva, Madrid, 1956. 374 páginas. / Ch. Bohler: El niño y su familia. Técnica de exploración familiar. Editorial Paidos. Buenos Aires, 1955, 191 páginas. / Paul V. Lemkau: Higiene Mental. Fondo de Cultura Económica de México, 1953. 397 páginas. / Orlando Fals-Borda: Peasant Society in the Colombian Andes: A Sociological Study of Saucio. GainesviIIe (University of Florida Press). 1955, 277 pags., ilustraciones, apéndices e índice analítico. / P. Bruno de Jesus Maria: Pecado, Confesión, Psicoanálisis (Estudios de Psicología Religiosa), Bilbao, 1956. Desclée de Brouwer, 235 pags. / A. Niedermayer: Compendio de Medicina Pastoral. Barcelona, 1955. Editorial Herder. Versión española de Ing. Rodrigo, revisada por el doctor I. Antich, 507 pags. / R. Amadou: La Parapsicología (Historia y Crítica). Buenos Aires, 1956. Prefacio de D. J. Van Lennep, profesor de Psicología en la Universidad Real de Utrecht. Versión castellana de Lia G. Ratto y Carlos A. Duval. Editorial Paidos. 409 páginas

Bibliografía

Viktor E. Frankl: Un psicólogo en el campo de concentración, Buenos Aires, 1955. Editorial Plantin / Viktor E. Frankl: La psicoterapia en la Práctica médica, Buenos Aires, 1956. Editorial Plantin, 287 pp.  / Viktor E. Frankl: El hombre incondicionado, Buenos Aires, Editorial Plantin, 184 pp. / Viktor E. Frankl: Homo patiens (Intento de una patodicea), Buenos Aires, 1955. Editorial Plantin, 167 pp. / Viktor E. Frankl: El Dios inconsciente. Buenos Aires, 1955. Editorial Plantin. / J. Nuttin: Psicoanálisis y concepción espiritualista del hombre. Traducción de la segunda edición francesa por el doctor E. García Moreno. Biblioteca Nueva, Madrid, 1956. 374 páginas. / Ch. Bohler: El niño y su familia. Técnica de exploración familiar. Editorial Paidos. Buenos Aires, 1955, 191 páginas. / Paul V. Lemkau: Higiene Mental. Fondo de Cultura Económica de México, 1953. 397 páginas. / Orlando Fals-Borda: Peasant Society in the Colombian Andes: A Sociological Study of Saucio. GainesviIIe (University of Florida Press). 1955, 277 pags., ilustraciones, apéndices e índice analítico. / P. Bruno de Jesus Maria: Pecado, Confesión, Psicoanálisis (Estudios de Psicología Religiosa), Bilbao, 1956. Desclée de Brouwer, 235 pags. / A. Niedermayer: Compendio de Medicina Pastoral. Barcelona, 1955. Editorial Herder. Versión española de Ing. Rodrigo, revisada por el doctor I. Antich, 507 pags. / R. Amadou: La Parapsicología (Historia y Crítica). Buenos Aires, 1956. Prefacio de D. J. Van Lennep, profesor de Psicología en la Universidad Real de Utrecht. Versión castellana de Lia G. Ratto y Carlos A. Duval. Editorial Paidos. 409 páginas

The Boom of cohabitation in Colombia and in the Andean Region : social and spatial patterns

In this chapter we use census microdata to document the rise in cohabitation in Colombia and in the Andean countries of Ecuador, Bolivia, Perú and Venezuela over the last four decades. We use multilevel logistic regression models to examine the effect of individual and contextual variables on cohabitation. We show the individual and contextual effects of social stratification, ethnicity and religion on cohabitation. Cohabitation levels follow a negative gradient with education and vary according to ethnic background. The Bolivian, Ecuadorian and Peruvian censuses reveal that the two largest ethnic groups (i.e. the Quechua and Aymara) have, controlling for other characteristics, the lowest incidence of cohabitation. By contrast, Afro-American populations show the highest levels of cohabitation. The joint use of individual- and contextual-level explanatory variables is sufficient to account for the majority of Bolivia's internal diversity regarding cohabitation, but not sufficient to account for the internal diversity identified in Colombia, Peru or Ecuador. Even after controls, residence in the Andes mountain areas continues to be a factor associated with lower levels of cohabitation. This invites further investigations on how the institutionalization of marriage occurred in the Andes

Evolution after Anti-TNF Discontinuation in Patients with Inflammatory Bowel Disease: A Multicenter Long-Term Follow-Up Study

OBJECTIVES:The aims of this study were to assess the risk of relapse after discontinuation of anti-tumor necrosis factor (anti-TNF) drugs in patients with inflammatory bowel disease (IBD), to identify the factors associated with relapse, and to evaluate the overcome after retreatment with the same anti-TNF in those who relapsed.METHODS:This was a retrospective, observational, multicenter study. IBD patients who had been treated with anti-TNFs and in whom these drugs were discontinued after clinical remission was achieved were included.RESULTS:A total of 1, 055 patients were included. The incidence rate of relapse was 19% and 17% per patient-year in Crohn''s disease and ulcerative colitis patients, respectively. In both Crohn''s disease and ulcerative colitis patients in deep remission, the incidence rate of relapse was 19% per patient-year. The treatment with adalimumab vs. infliximab (hazard ratio (HR)=1.29; 95% confidence interval (CI)=1.01-1.66), elective discontinuation of anti-TNFs (HR=1.90; 95% CI=1.07-3.37) or discontinuation because of adverse events (HR=2.33; 95% CI=1.27-2.02) vs. a top-down strategy, colonic localization (HR=1.51; 95% CI=1.13-2.02) vs. ileal, and stricturing behavior (HR=1.5; 95% CI=1.09-2.05) vs. inflammatory were associated with a higher risk of relapse in Crohn''s disease patients, whereas treatment with immunomodulators after discontinuation (HR=0.67; 95% CI=0.51-0.87) and age (HR=0.98; 95% CI=0.97-0.99) were protective factors. None of the factors were predictive in ulcerative colitis patients. Retreatment of relapse with the same anti-TNF was effective (80% responded) and safe.CONCLUSIONS:The incidence rate of inflammatory bowel disease relapse after anti-TNF discontinuation is relevant. Some predictive factors of relapse after anti-TNF withdrawal have been identified. Retreatment with the same anti-TNF drug was effective and safe

Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in treatment-experienced, virologically-suppressed adults living with HIV-1

Altres ajuts: This study was sponsored by Janssen.Darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) 800/150/200/10 mg was investigated through 96 weeks in EMERALD (NCT02269917). Virologically-suppressed, HIV-1-positive treatment-experienced adults (previous non-darunavir virologic failure [VF] allowed) were randomized (2:1) to D/C/F/TAF or boosted protease inhibitor (PI) plus emtricitabine/tenofovir-disoproxil-fumarate (F/TDF) over 48 weeks. At week 52 participants in the boosted PI arm were offered switch to D/C/F/TAF (late-switch, 44 weeks D/C/F/TAF exposure). All participants were followed on D/C/F/TAF until week 96. Efficacy endpoints were percentage cumulative protocol-defined virologic rebound (PDVR; confirmed viral load [VL] ≥50 copies/mL) and VL < 50 copies/mL (virologic suppression) and ≥50 copies/mL (VF) (FDA-snapshot analysis). Of 1141 randomized patients, 1080 continued in the extension phase. Few patients had PDVR (D/C/F/TAF: 3.1%, 24/763 cumulative through week 96; late-switch: 2.3%, 8/352 week 52-96). Week 96 virologic suppression was 90.7% (692/763) (D/C/F/TAF) and 93.8% (330/352) (late-switch). VF was 1.2% and 1.7%, respectively. No darunavir, primary PI, tenofovir or emtricitabine resistance-associated mutations were observed post-baseline. No patients discontinued for efficacy-related reasons. Few discontinued due to adverse events (2% D/C/F/TAF arm). Improved renal and bone parameters were maintained in the D/C/F/TAF arm and observed in the late-switch arm, with small increases in total cholesterol/high-density-lipoprotein-cholesterol ratio. A study limitation was the lack of a control arm in the week 96 analysis. Through 96 weeks, D/C/F/TAF resulted in low PDVR rates, high virologic suppression rates, very few VFs, and no resistance development. Late-switch results were consistent with D/C/F/TAF week 48 results. EMERALD week 96 results confirm the efficacy, high genetic barrier to resistance and safety benefits of D/C/F/TAF

Effects of the neurogranin variant rs12807809 on thalamocortical morphology in schizophrenia

10.1371/journal.pone.0085603PLoS ONE812-POLN

Strong Carbon Features and a Red Early Color in the Underluminous Type Ia SN 2022xkq

We present optical, infrared, ultraviolet, and radio observations of SN 2022xkq, an underluminous fast-declining type Ia supernova (SN Ia) in NGC 1784 ($\mathrm{D}\approx31$ Mpc), from $<1$ to 180 days after explosion. The high-cadence observations of SN 2022xkq, a photometrically transitional and spectroscopically 91bg-like SN Ia, cover the first days and weeks following explosion which are critical to distinguishing between explosion scenarios. The early light curve of SN 2022xkq has a red early color and exhibits a flux excess which is more prominent in redder bands; this is the first time such a feature has been seen in a transitional/91bg-like SN Ia. We also present 92 optical and 19 near-infrared (NIR) spectra, beginning 0.4 days after explosion in the optical and 2.6 days after explosion in the NIR. SN 2022xkq exhibits a long-lived C I 1.0693 $\mu$m feature which persists until 5 days post-maximum. We also detect C II $\lambda$6580 in the pre-maximum optical spectra. These lines are evidence for unburnt carbon that is difficult to reconcile with the double detonation of a sub-Chandrasekhar mass white dwarf. No existing explosion model can fully explain the photometric and spectroscopic dataset of SN 2022xkq, but the considerable breadth of the observations is ideal for furthering our understanding of the processes which produce faint SNe Ia.Comment: 38 pages, 16 figures, accepted for publication in ApJ, the figure 15 input models and synthetic spectra are now available at https://zenodo.org/record/837925

Evolution of the use of corticosteroids for the treatment of hospitalised COVID-19 patients in Spain between March and November 2020: SEMI-COVID national registry

Objectives: Since the results of the RECOVERY trial, WHO recommendations about the use of corticosteroids (CTs) in COVID-19 have changed. The aim of the study is to analyse the evolutive use of CTs in Spain during the pandemic to assess the potential influence of new recommendations. Material and methods: A retrospective, descriptive, and observational study was conducted on adults hospitalised due to COVID-19 in Spain who were included in the SEMI-COVID- 19 Registry from March to November 2020. Results: CTs were used in 6053 (36.21%) of the included patients. The patients were older (mean (SD)) (69.6 (14.6) vs. 66.0 (16.8) years; p < 0.001), with hypertension (57.0% vs. 47.7%; p < 0.001), obesity (26.4% vs. 19.3%; p < 0.0001), and multimorbidity prevalence (20.6% vs. 16.1%; p < 0.001). These patients had higher values (mean (95% CI)) of C-reactive protein (CRP) (86 (32.7-160) vs. 49.3 (16-109) mg/dL; p < 0.001), ferritin (791 (393-1534) vs. 470 (236- 996) µg/dL; p < 0.001), D dimer (750 (430-1400) vs. 617 (345-1180) µg/dL; p < 0.001), and lower Sp02/Fi02 (266 (91.1) vs. 301 (101); p < 0.001). Since June 2020, there was an increment in the use of CTs (March vs. September; p < 0.001). Overall, 20% did not receive steroids, and 40% received less than 200 mg accumulated prednisone equivalent dose (APED). Severe patients are treated with higher doses. The mortality benefit was observed in patients with oxygen saturation </=90%. Conclusions: Patients with greater comorbidity, severity, and inflammatory markers were those treated with CTs. In severe patients, there is a trend towards the use of higher doses. The mortality benefit was observed in patients with oxygen saturation </=90%

Large scale multifactorial likelihood quantitative analysis of BRCA1 and BRCA2 variants: An ENIGMA resource to support clinical variant classification

The multifactorial likelihood analysis method has demonstrated utility for quantitative assessment of variant pathogenicity for multiple cancer syndrome genes. Independent data types currently incorporated in the model for assessing BRCA1 and BRCA2 variants include clinically calibrated prior probability of pathogenicity based on variant location and bioinformatic prediction of variant effect, co-segregation, family cancer history profile, co-occurrence with a pathogenic variant in the same gene, breast tumor pathology, and case-control information. Research and clinical data for multifactorial likelihood analysis were collated for 1,395 BRCA1/2 predominantly intronic and missense variants, enabling classification based on posterior probability of pathogenicity for 734 variants: 447 variants were classified as (likely) benign, and 94 as (likely) pathogenic; and 248 classifications were new or considerably altered relative to ClinVar submissions. Classifications were compared with information not yet included in the likelihood model, and evidence strengths aligned to those recommended for ACMG/AMP classification codes. Altered mRNA splicing or function relative to known nonpathogenic variant controls were moderately to strongly predictive of variant pathogenicity. Variant absence in population datasets provided supporting evidence for variant pathogenicity. These findings have direct relevance for BRCA1 and BRCA2 variant evaluation, and justify the need for gene-specific calibration of evidence types used for variant classification